![](\"https:\/\/mms.businesswire.com\/media\/20260610224927\/en\/2826582\/5\/3F1A0969.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260610224927\/en\/2826541\/5\/cropped-Orionis-Logo-web-black-01_noTM.jpg\"){kind=logo}
<\/a><\/a>\nUnder the terms of the agreement, Novartis and Orionis will use Orionis\u2019s Allo-Glue\u2122 platform, together with its AI-driven discovery engine, to accelerate target and ligase profiling and molecular glue optimization. These integrated capabilities enable the systematic discovery of small molecule glues that modulate therapeutic targets through induced proximity mechanisms. Orionis will receive an upfront payment of USD 40 million and is eligible to receive research, development, and commercial milestone payments of up to USD 1.4 billion, in addition to tiered royalties on net sales of collaboration products.<\/p>
\n\u201cWe are proud to renew and expand our collaboration with Novartis,\u201d said Niko Kley, Chief Executive Officer of Orionis Biosciences. \u201cHaving such a partner continue to engage deeply with us is a strong validation of the value of our molecular glue platform and the progress we have achieved toward rational and scalable discovery of this emerging drug class.\u201d<\/p>
\n\u201cOur recent advances in AI and robotic automation have accelerated all aspects of molecular glue discovery, from systematic prioritization of productive target\u2013ligase pairs to glue candidate discovery and optimization,\u201d said Riccardo Sabatini, Chief Data Scientist at Orionis Biosciences. \u201cThis is exactly the kind of platform maturity that makes collaborations like this possible.\u201d<\/p>
\n\u201cWe are excited to deepen our collaboration with Orionis and to explore the full potential of molecular glue modalities across multiple therapeutic areas,\u201d said John Tallarico, Head of Discovery Sciences at Novartis. \u201cThe Orionis platform offers an opportunity to rapidly uncover and design molecular glue mechanisms, enabling us to expand the horizon of targetable biology for future therapies.\u201d<\/p>
\nAbout Orionis Biosciences<\/b><\/p>
\nOrionis Biosciences is a clinical\u2011stage life sciences company pioneering the systematic discovery and design of small and large molecule therapeutic modalities that act through molecular proximity mechanisms to impact challenging and traditionally elusive disease targets. The company\u2019s proprietary Allo\u2011Glue\u2122 small molecule platform enables functional reprogramming of proteins within living cells. Orionis has established advanced capabilities in chemical biology, artificial intelligence\u2011driven molecular design, and large\u2011scale cell\u2011based interrogation, enabling rational discovery of molecular glues for degradation, stabilization or modulation of target proteins. Orionis is advancing a diversified pipeline of programs in oncology and immunology and collaborates with leading biopharmaceutical companies to translate its technologies into transformative medicines.<\/p>
\nTo learn more, please visit www.orionisbio.com<\/a>.<\/p>